Системная красная волчанка

1. Uramoto KM, Mitchet CJ Jr, Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum. 1999 Jan;42(1):46-50.Полный текст  Аннотация

2. Siegel M, Lee SL. The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum. 1973;3(1):1-54. Аннотация

3. Mitchet CJ Jr, McKenna CH, Elveback LR, et al. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1985 Feb;60(2):105-13. Аннотация

4. Nived O, Sturfelt G, Wollheim F. Systemic lupus erythematosus in an adult population in southern Sweden: incidence, prevalence and validity of ARA revised classification criteria. Br J Rheumatol. 1985 May;24(2):147-54. Аннотация

5. Johnson AE, Gordon C, Palmer RG, et al. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum. 1995 Apr;38(4):551-8. Аннотация

6. Nai-Zheng Z. Epidemiology of systemic lupus erythematosus (SLE) in China. Proceedings of the 2nd International Conference on SLE, Tokyo: Professional Postgraduate Services, Int. 1989:29-31.

7. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308-18. Аннотация

8. Masi AT, Kaslow RA. Sex effects in SLE: a clue to pathogenesis. Arthritis Rheum. 1978 May;21(4):480-4. Аннотация

9. Lawrence JS, Martins CL, Drake GL. A family survey of lupus erythematosus. 1. Heritability. J Rheumatol. 1987 Oct;14(5):913-21. Аннотация

10. Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992 Mar;35(3):311-8. Аннотация

11. Taylor PR, Carugati A, Fadok VA, et al. Heirarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med. 2000 Aug 7;192(3):359-66.Полный текст  Аннотация

12. Reveille JD. The molecular genetics of systemic lupus erythematosus and Sjögren's syndrome. Curr Opin Rheumatol. 1992 Oct;4(5):644-56. Аннотация

13. Demirci FY, Manzi S, Ramsey-Goldman R, et al. Association of a common interferon regulatory factor 5 (IRF5) variant with increased risk of systemic lupus erythematosus (SLE). Ann Hum Genet. 2007 May;71(Pt 3):308-11.Полный текст  Аннотация

14. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am. 1994 Feb;20(1):61-86. Аннотация

15. Blomgren SE, Condemi JJ, Vaughan JH. Procainamide-induced lupus erythematosus: clinical and laboratory observations. Am J Med. 1972 Mar;52(3):338-48. Аннотация

16. Sclienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus: a systematic review. Dermatology. 2000;200(3):223-31. Аннотация

17. Gordon MM, Porter D. Minocycline induced lupus: case series in the West of Scotland. J Rheumatol. 2001 May;28(5):1004-6. Аннотация

18. McKellar G, Porter D, Burden D. Terbinafine as a cause of cutaneous lupus erythematosus. Rheumatology (Oxford). 2004 Feb;43(2):249. Аннотация

19. Gunnarsson I, Nordmark B, Hassan Bakri A et al. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. Rheumatology (Oxford). 2000 Aug;39(8):886-93.Полный текст  Аннотация

20. Siddiqui MA, Khan IA. Isoniazid-induced lupus erythematosus presenting with cardiac tamponade. Am J Ther. 2002 Mar-Apr;9(2):163-5. Аннотация

21. Scheinfeld N. Impact of phenytoin therapy on the skin and skin disease. Expert Opin Drug Saf. 2004 Nov;3(6):655-65. Аннотация

22. Pelizza L, De Luca P, La Pesa M, et al. Drug-induced systemic lupus erythematosus after 7 years of treatment with carbamazepine. Acta Biomed. 2006 Apr;77(1):17-9. Аннотация

23. James JA, Kaufman KM, Farris AD, et al. An increased prevalence of Ebstein Barr virus infection in young patients suggests a possible aetiology for SLE. J Clin Invest. 1997 Dec 15;100(12):3019-26.Полный текст  Аннотация

24. Chan OT, Madio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev. 1999 Jun;169:107-21. Аннотация

25. Shevack EM. Regulatory T cells in autoimmunity. Annu Rev Immunol. 2000;18:423-49. Аннотация

26. Munoz L, van Bavel C, Franz S, et al. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus. 2008 May;17(5):371-5. Аннотация

27. Grimaldi CM. Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells. Curr Opin Rheumatol. 2006 Sep;18(5):456-61. Аннотация

28. Jungers P, Dougados M, Pelissier C, et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum. 1982 Jun;25(6):618-23. Аннотация

29. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005 Jun 21;142(12 Pt 1):953-62. Аннотация

30. Kaslow RA, Masi AT. Age, sex, and race effects on mortality from systemic lupus erythematosus in the United States. Arthritis Rheum. 1978 May;21(4):473-9. Аннотация

31. Ginzler EM, Diamond HS, Weiner M, et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum. 1982 Jun;25(6):601-11. Аннотация

32. Boodhoo KD, Liu S, Zuo X. Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Medicine (Baltimore). 2016 Jul;95(29):e4272.Полный текст  Аннотация

33. Font J, Pallares L, Cervera R, et al. Systemic lupus erythematosus in the elderly: clinical and immunological characteristics. Ann Rheum Dis. 1991 Oct;50(10):702-5.Полный текст  Аннотация

34. Molokhia M, Hoggart C, Patrick AL, et al. Relation of risk of SLE to west African admixture in a Caribbean population. Hum Genet. 2003 Mar;112(3):310-8. Аннотация

35. Deabndt M, Vittecoq O, Descamps V, et al. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol. 2003 Feb;22(1):56-61. Аннотация

36. Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol. 2005 Apr;24(2):178-81. Аннотация

37. D'Cruz DP, Khamashta MA, Hughes GRV. Systemic lupus erythematosus. Lancet. 2007 Feb 17;369(9561):587-96. Аннотация

38. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998 May;41(5):778-99. Аннотация

39. Jiang F, Li S, Jia C. Smoking and the risk of systemic lupus erythematosus: an updated systematic review and cumulative meta-analysis. Clin Rheumatol. 2015 Nov;34(11):1885-92. Аннотация

40. Harel-Meir M. Sherer Y, Shoenfeld Y. Tobacco smoking and autoimmune disease. Nat Clin Pract Rheumatol. 2007 Dec;3(12):707-15. Аннотация

41. Montes RA, Mocarzel LO, Lanzieri PG, et al. Smoking and its association with morbidity in systemic lupus erythematosus evaluated by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index: preliminary data and systematic review. Arthritis Rheumatol. 2016 Feb;68(2):441-8.Полный текст  Аннотация

42. Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008 Feb;67(2):195-205.Полный текст  Аннотация

43. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725. Аннотация

44. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-86.Полный текст  Аннотация

45. McKinley PS, Ouellette SC, Winkel GH. The contributions of disease activity, sleep patterns and depression to fatigue in SLE: a proposed model. Arthritis Rheum. 1995 Jun;38(6):826-34. Аннотация

46. Zandman-Goddard G, Schoenfeld Y. SLE and infections. Clin Rev Allergy Immunol. 2003 Aug;25(1):29-40. Аннотация

47. Bernatsky S. Boivin JF. Joseph L, et al. Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum. 2005 Oct 15;53(5):781-4.Полный текст  Аннотация

48. Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore). 1971 Mar;50(2):85-95. Аннотация

49. Vitali C, Doria A, Tincani A. International survey on the management of patients with SLE. I. General data on the participating centers and the results of a questionnaire regarding mucocutaneous involvement. Clin Exp Rheumatol. 1996 Nov-Dec;14(suppl 16):S17-22. Аннотация

50. Dubois EL, Tuffanelli DL. Clinical manifestations of SLE: computer analysis of 520 cases. JAMA. 1964 Oct 12;190:104-11. Аннотация

51. Feinglass EJ, Arnett FC, Dorsch CA, et al. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore). 1976 Jul;55(4):323-39. Аннотация

52. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with SLE: comparison with the Framingham study. Am J Epidemiol. 1997 Mar 1;145(5):408-15.Полный текст  Аннотация

53. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999 Feb;42(2):338-46.Полный текст  Аннотация

54. Memet B, Ginzler EM. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med. 2007 Aug;28(4):441-50. Аннотация

55. Duron L, Cohen-Aubart F, Diot E, et al. Shrinking lung syndrome associated with systemic lupus erythematosus: a multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. Autoimmun Rev. 2016 Oct;15(10):994-1000. Аннотация

56. Beyan E, Beyan C, Turan M. Hematological presentation in systemic lupus erythematosus and its relationship with disease activity. Hematology. 2007 Jun;12(3):257-61. Аннотация

57. Hallegua DS, Wallace DJ. Gastrointestinal manifestations of systemic lupus erythematosus. Curr Opin Rheumatol. 2000 Sep;12(5):379-85. Аннотация

58. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997 Sep;40(9):1601-11. Аннотация

59. Smeenk R, Brinkman K, van den Brink H, et al. Antibodies to DNA in patients with systemic lupus erythematosus: their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol. 1990 Mar;9(1 suppl 1):100-10. Аннотация

60. Eaton RB, Schnneider G, Schur PH. Enzyme immunoassay for antibodies to native DNA. Specificity and quality of antibodies. Arthritis Rheum. 1983 Jan;26(1):52-62. Аннотация

61. Weening JJ, D'Agati V, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004 Feb;15(2):241-50.Полный текст  Аннотация

62. Hochberg MC, Boyd RE, Ahearn JM, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore). 1985 Sep;64(5):285-95. Аннотация

63. Schneebaum AN, Singleton JD, West SG, et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med. 1991 Jan;90(1):54-62. Аннотация

64. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002 Apr;46(4):1019-27. Аннотация

65. von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum. 1995 Apr;24(5):323-58. Аннотация

66. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the anti-phospholipid syndrome. Blood. 2007 Jan 15;109(2):422-30.Полный текст  Аннотация

67. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271-7. Аннотация

68. Rodríguez Huerta MD, Trujillo-Martín MM, Rúa-Figueroa Í, et al. Healthy lifestyle habits for patients with systemic lupus erythematosus: a systemic review. Semin Arthritis Rheum. 2016 Feb;45(4):463-70. Аннотация

69. Bruce IN, Mak VC, Hallett DC, et al. Factors associated with fatigue in patients with systemic lupus erythematosus. Ann Rheum Dis. 1999 Jun;58(6):379-81.Полный текст  Аннотация

70. Zonana-Nacach A, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups, VI: factors associated with fatigue within five year of criteria diagnosis. Lupus. 2000;9(2):101-9. Аннотация

71. William HJ, Egger MJ, Singer JZ, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol. 1994 Aug;21(8):1457-62. Аннотация

72. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991 Jan 17;324(3):150-4.Полный текст  Аннотация

73. Carneiro JR, Sato EI. Double-blind, randomised, placebo controlled trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999 Jun;26(6):1275-9. Аннотация

74. Herzinger T, Plewig G, Röcken M. Use of sunscreens to protect against ultra-violet induced lupus erythematosus. Arthritis Rheum. 2004 Sep;50(9):3045-6.Полный текст  Аннотация

75. Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013 Jan;61(1):74-87. Аннотация

76. Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018 Jun 29;(6):CD002922.Полный текст  Аннотация

77. Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016 Jan;75(1):30-6. Аннотация

78. Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015 Jan 6;162(1):18-26. Аннотация

79. Tian SY, Feldman BM, Beyene J, et al. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. J Rheumatol. 2014 Oct;41(10):1998-2007. Аннотация

80. Zhang X, Ji L, Yang L, et al. The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis. Int Urol Nephrol. 2016 May;48(5):731-43. Аннотация

81. Lee YH, Song GG. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials. Lupus. 2015 Dec;24(14):1520-8. Аннотация

82. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64:797-808.Полный текст  Аннотация

83. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012 Nov;71(11):1771-82.Полный текст  Аннотация

84. Kasitanon N, Fine DM, Haas M, et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15(6):366-70. Аннотация

85. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppresion in lupus nephritis: results from the MAINTAIN Nephritis trial. Ann Rheum Dis. 2010 Dec;69(12):2083-9.Полный текст  Аннотация

86. Maneiro JR, Lopez-Canoa N, Salgado E, et al. Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis. Rheumatology (Oxford). 2014 May;53(5):834-8. Аннотация

87. Tian SY, Feldman BM, Beyene J, et al. Immunosuppressive therapies for the maintenance treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. J Rheumatol. 2015 Aug;42(8):1392-400. Аннотация

88. Tamirou F, D'Cruz D, Sangle S, et al; MAINTAIN Nephritis Trial Group. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016 Mar;75(3):526-31.Полный текст  Аннотация

89. Rodríguez SC, Olguín AM, Miralles CP, et al. Characteristics of meningitis caused by ibuprofen: report of 2 cases with recurrent episodes and review of the literature. Medicine (Baltimore). 2006 Jul;85(4):214-20. Аннотация

90. Antman EM, Bennet JS, Daugherty A, et al. Use of non-steroidal antiinflammatory drugs, an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007 Mar 27;115(12):1634-42.Полный текст  Аннотация

91. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001 Dec 20;345(25):1809-17.Полный текст  Аннотация

92. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos. 2001 Apr;29(4 Pt 2):601-5.Полный текст  Аннотация

93. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15;61(9):1168-78.Полный текст  Аннотация

94. Van Vollenhoven R, Zamani O, Wallace DJ, et al. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study. Ann Rheum Dis. 2010;69(suppl 3):74.Полный текст

95. Petri M, Levy RA, Merrill JT, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares, and prednisone use in patients with seropositive SLE: combined efficacy results from the phase 3 BLISS-52 and -76 studies. Arthritis Rheum. 2010;62(suppl 10):190.

96. Manzi S, Sánchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012 Nov;71(11):1833-8.Полный текст  Аннотация

97. Sciascia S, Radin M, Yazdany J, et al. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. Autoimmun Rev. 2017 Mar;16(3):287-93.Полный текст  Аннотация

98. Merrill JT, Ginzler EM, Wallace DJ, et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Oct;64(10):3364-73.Полный текст  Аннотация

99. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721-31. Аннотация

100. Boyce EG, Fusco BE. Belimumab: review of use in systemic lupus erythematosus. Clin Ther. 2012 May;34(5):1006-22. Аннотация

101. Wei LQ, Liang YG, Zhao Y, et al. Efficacy and safety of belimumab plus standard therapy in patients with systemic lupus erythematosus: a meta-analysis. Clin Ther. 2016 May;38(5):1134-40. Аннотация

102. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8(3):R83.Полный текст  Аннотация

103. Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002 Oct;46(10):2673-7.Полный текст  Аннотация

104. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003 Feb;48(2):455-9.Полный текст  Аннотация

105. Rovin BH, Furie R, Latinis K, et al; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 Apr;64(4):1215-26.Полный текст  Аннотация

106. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011 Jun;20(7):709-16. Аннотация

107. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan;62(1):222-33.Полный текст  Аннотация

108. Weidenbusch M, Römmele C, Schröttle A, et al. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013 Jan;28(1):106-11.Полный текст  Аннотация

109. Furie RA, Leon G, Thomas M, et al; PEARL-SC Study. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015 Sep;74(9):1667-75. Аннотация

110. Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016 Jan;75(1):196-202. Аннотация

111. Khamashta M, Merrill JT, Werth VP, et al; CD1067 study investigators. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Nov;75(11):1909-16.Полный текст  Аннотация

112. Merrill JT, Wallace DJ, Petri M, et al; Lupus Interferon Skin Activity (LISA) Study Investigators. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70(11):1905-13. Аннотация

113. Department of Health. Clinical guidelines for immunoglobulin use (2nd edition). May 2008 [internet publication].Полный текст

114. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5 year period. A multicentre prospective study of 1000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999 May;78(3):167-75. Аннотация

115. Cervera R, Abarca-Costalago M, Abramovicz D, et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". AAutoimmun Rev. 2006 Mar;5(3):180-6. Аннотация

116. Lee YH, Choi SJ, Ji JD, et al. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016 Jun;25(7):727-34. Аннотация

117. Fors Nieves CE, Izmirly PM. Mortality in systemic lupus erythematosus: an updated review. Curr Rheumatol Rep. 2016 Apr;18(4):21. Аннотация

118. Qian J, Wang Y, Huang C, et al. Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: a PRISMA-compliant systematic review and meta-analysis. Autoimmun Rev. 2016 Mar;15(3):250-7. Аннотация

119. Ballocca F, D'Ascenzo F, Moretti C, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol. 2015 Nov;22(11):1435-41.Полный текст  Аннотация

120. Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Ann Rheum Dis. 2008 Jan;67(1):74-9. Аннотация

121. Schneider V, Levesque LE, Zhang B, et al. Association of selective and conventional non-steroidal anti inflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006 Nov 1;164(9):881-9.Полный текст  Аннотация

122. Breuer GS, Baer A, Dahan D, Nesher G. Lupus-associated pancreatitis. Autoimmun Rev. 2006 May;5(5):314-8. Аннотация

123. Nesher G, Breuer GS, Temprano K, et al. Lupus-associated pancreatitis. Semin Arthritis Rheum. 2006 Feb;35(4):260-7. Аннотация

124. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995 Apr 13;332(15):993-7.Полный текст  Аннотация

125. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus. 2004;13(9):673-8. Аннотация

126. Manger K, Wildt L, Kalden JR, et al. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev. 2006 Apr;5(4):269-72. Аннотация

127. Soares PM, Borba EF, Bonfa E, et al. Gonad evaluation in male systemic lupus erythematosus. Arthritis Rheum. 2007 Jul;56(7):2352-61.Полный текст  Аннотация

128. Oshiro BT, Silver RM, Scott JR, et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol. 1996 Apr;87(4):489-93. Аннотация

129. Out HJ, Bruinse HW, Christiaens GC, et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol. 1992 Jul;167(1):26-32. Аннотация

130. Kutteh WH, Lyda EC, Abraham SM, et al. Association of anticardiolipin antibodies and pregnancy loss in women with systemic lupus erythematosus. Fertil Steril. 1993 Sep;60(3):449-55. Аннотация

131. Kozora E, Ellison MC, West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum. 2006 Aug 15;55(4):628-35.Полный текст  Аннотация

132. Wang X, Yan S, Liu C, et al. Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Osteoporos Int. 2016 Apr;27(4):1413-23. Аннотация

133. Henegar CE, Eudy AM, Kharat V, et al. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus. 2016 May;25(6):617-26. Аннотация

134. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptive in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2550-8.Полный текст  Аннотация

135. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2539-49.Полный текст  Аннотация

136. Clowse ME, Magder L, Whitter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006 Nov;54(11):3640-7.Полный текст  Аннотация

137. Battafarano DF, Battafarano NJ, Larsen L et al. Antigen specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998 Oct;41(10):1828-34. Аннотация

138. Holvast A, Huckriede A, Wilschut J, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis. 2006 Jul;65(7):913-8.Полный текст  Аннотация

139. Huang Y, Wang H, Wan L, et al. Is systemic lupus erythematosus associated with a declined immunogenicity and poor safety of influenza vaccination? A systematic review and meta-analysis. Medicine (Baltimore). 2016 May;95(19):e3637.Полный текст  Аннотация

140. Pugès M, Biscay P, Barnetche T, et al. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology (Oxford). 2016 Sep;55(9):1664-72.Полный текст  Аннотация

141. Senecal JL, Bertrand C, Coutlee F. Severe exacerbation of systemic lupus erythematosus after hepatitis B vaccination and importance of pneumococcal vaccination in patients with autosplenectomy. Arthritis Rheum. 1999 Jun;42(6):1307-8.Полный текст  Аннотация